Alpha Interferon Articles & Analysis
5 news found
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will present clinical data from its Phase 1/2a dose-escalation study of its clinical-stage candidate Temferon™ in patients with glioblastoma multiforme (GBM) who have an unmthylated MGMT gene promotor (uMGMT-GBM) at the ...
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present enhancements to its proprietary cytoDRIVE® technology during a poster presentation at the 25th ASGCT Annual Meeting. The conference is being hosted in Washington, D.C., and virtually, May 16-19, 2022. The data to be presented outline next-generation advancements ...
A ‘Temferon signature’ – markers of interferon-alpha responses and macrophage repolarization – was also highlighted in Temferon-treated patients compared to patients who received current standard-of-care for GBM. ...
Genenta's Temferon™, a lentivirus based hematopoietic stem progenitor cell immuno gene & cell therapy enabling controlled and targeted interferon-α expression within cancers, will be discussed as a potential treatment solution for glioblastoma patients. ...
NG- 641 is a systemically administered product that encodes for the tumor selective delivery of an anti-FAP/anti-CD3 bispecific, interferon alpha, CXCL9 and CXCL10. Fibroblast Activating Protein(FAP) is selectively upregulated on the cancer associated fibroblasts (CAF) that play an important role in the immune suppressive tumor microenvironment found in many ...